Equillium ups ATM facility to $75M from $21.95M; prior sales $0.96M

Equillium, Inc.

Filed prospectus supplement to increase aggregate offering price of common stock under existing Sales Agreement to $75M.
Sales Agreement with LifeSci Capital LLC, dated Oct 2023, amended Aug 2025, governs the at-the-market offering.
Previously sold 1,719,485 shares for aggregate gross proceeds of approximately $0.96M.
New supplement amends prior ATM prospectus dated Jan 2023, as supplemented Oct 2023 and Feb 2024.
No specific use of proceeds stated in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.